News

Blog

A New Treatment Option for NET Patients

The U.S. Food and Drug Administration (FDA) has approved cabozantinib for the treatment of previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors

Read More »